Cardiovascular / Natriuretic Research Peptides Guide
Overview
This guide covers 3 research peptides in the Cardiovascular / Natriuretic category. Each compound is evaluated on its evidence base, mechanism, safety profile, and current clinical status.
Nesiritide — FDA Approved (Declining Use)
Evidence: A | Status: FDA-approved (Natrecor, August 2001) for acute decompensated heart failure. Use declined significantly after ASCEND-HF trial (2011) showed no mortality benefit.
Nesiritide is a recombinant form of human B-type natriuretic peptide (BNP), a 32-amino-acid peptide (MW ~3464 g/mol) with a 17-residue disulfide ring structure.
Use cases: Acute Heart Failure, Hemodynamic Support
Atrial Natriuretic Peptide — Approved in Japan / Established Biomarker
Evidence: B | Status: Carperitide (recombinant hANP) approved in Japan (1995) for acute heart failure. Not approved in the US, EU, or other Western markets.
Atrial natriuretic peptide (ANP) is a 28-amino-acid hormone (MW ~3080 g/mol) secreted primarily by atrial cardiomyocytes in response to atrial stretch from volume overload. It is a key regulator of blood volume, sodium balance, and blood pressure.
Use cases: Acute Heart Failure (Japan), Cardiac Biomarker, Cardiovascular Research
B-type Natriuretic Peptide — Established Biomarker / Therapeutic Basis
Evidence: B | Status: Established diagnostic biomarker for heart failure. Recombinant form (nesiritide) is FDA-approved for acute decompensated heart failure.
B-type natriuretic peptide (BNP) is a 32-amino-acid cardiac hormone (MW ~3464 g/mol) secreted primarily by ventricular cardiomyocytes in response to myocardial wall stress from volume overload or pressure overload.
Use cases: Heart Failure Diagnosis, Cardiac Biomarker, Cardiovascular Research